Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of classifying reproductive medications as controlled substances: A deep dive into the Louisiana law.

Journal of the American Pharmacists Association : JAPhA·2025
Same author

Resting Heart Rate Variability, Inflammation, and Insulin Resistance in Overweight and Obese Adolescents.

Metabolic syndrome and related disorders·2016
Same author

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil.

Patient preference and adherence·2015
Same author

Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2014
Same author

Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus.

Expert review of clinical pharmacology·2014
Same author

Rapid, simple assay for ziprasidone mesylate in extemporaneously compounded oral solutions.

International journal of pharmaceutical compounding·2013
Same journal

Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

The Annals of pharmacotherapy·2026
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
See all related articles

Related Experiment Videos

Inflammation in chronic heart failure.

Roy C Parish1, Jeffery D Evans

  • 1Department of Clinical and Administrative Sciences, College of Pharmacy, The University of Louisiana, Monroe, LA, USA. rparis@lsuhsc.edu

The Annals of Pharmacotherapy
|May 15, 2008
PubMed
Summary
This summary is machine-generated.

Chronic low-grade inflammation is linked to heart failure (HF) symptoms like reduced function and autonomic dysfunction. Therapies targeting inflammation, such as statins, may offer new treatment options for HF patients.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Immunology
  • Internal Medicine

Background:

  • Inflammatory processes are increasingly recognized as significant contributors to chronic heart failure (HF).
  • Key inflammatory mediators, including cytokines and uric acid, share physiological effects with HF manifestations.
  • The precise causal role of inflammation in HF pathogenesis remains under investigation.

Purpose of the Study:

  • To review and summarize the scientific literature on the association between inflammatory processes and chronic heart failure.
  • To explore the relationship between inflammatory mediators and the clinical features of HF.

Main Methods:

  • Comprehensive literature search of PubMed/MEDLINE databases from 1966 to January 2008.
  • Keywords included terms related to heart failure, inflammation, specific inflammatory mediators (cytokines, TNF-alpha), and relevant medications.
  • Analysis of 87 selected English-language articles focusing on inflammation in HF.

Main Results:

  • Elevated inflammatory mediators correlate with HF features such as reduced cardiac contractility, endothelial dysfunction, and insulin resistance.
  • The direct causative link between inflammation and HF symptoms is not definitively established.
  • Current HF therapies often reduce circulating cytokine levels, but further studies are needed to confirm the clinical significance of these effects.

Conclusions:

  • Chronic low-grade inflammation interconnects myocardial dysfunction, autonomic dysfunction, and glucose intolerance in HF.
  • Targeting inflammation with drugs like statins, pentoxifylline, and urate-lowering agents shows promise for improving HF treatment.
  • Further clinical research is warranted to validate anti-inflammatory strategies in HF management.